Tag: NATiV3
Inventiva: Lifting of the pause for the NATiV3 study
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Inventiva: lifting of the pause for the NATiV3 study – 03/08/2024 at 3:25 p.m.
(CercleFinance.com) – Inventiva announces the lifting of the previously announced voluntary pause in screening and randomization for its NATiV3 clinical study, evaluating its lanifibranor in NASH (non-alcoholic fatty liver disease)…
Inventiva: pause lifted for the NATiV3 study
(CercleFinance.com) – Inventiva announces the lifting of the previously announced voluntary pause in screening and randomization for its NATiV3 clinical study, evaluating its lanifibranor in NASH (non-alcoholic fatty liver disease)…
Inventiva announces the resumption of screening in the Phase III clinical study, NATiV3, evaluating lanifibranor in NASH – 03/07/2024 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva publishes its preliminary financial information for the 2023 fiscal year¹ and provides an update on its NATiV3 clinical study – 02/15/2024 at 10:35 p.m.
Daix (France), Long Island City (New York, United States), February 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical study and provides an update on its clinical development program – 12/20/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), December 20, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…